[go: up one dir, main page]

MA30066B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA30066B1
MA30066B1 MA31050A MA31050A MA30066B1 MA 30066 B1 MA30066 B1 MA 30066B1 MA 31050 A MA31050 A MA 31050A MA 31050 A MA31050 A MA 31050A MA 30066 B1 MA30066 B1 MA 30066B1
Authority
MA
Morocco
Prior art keywords
vaccine
relates
infant
pneumococcal
capsular saccharide
Prior art date
Application number
MA31050A
Other languages
English (en)
Inventor
Ralph Leon Biemans
Nathalie Marie-Josephe Garcon
Philippe Vincent Hermand
Jan Poolman
Mechelen Marcelle Paulette Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39133667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30066(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526232A external-priority patent/GB0526232D0/en
Priority claimed from GB0607087A external-priority patent/GB0607087D0/en
Priority claimed from GBGB0607088.2A external-priority patent/GB0607088D0/en
Priority claimed from GB0609902A external-priority patent/GB0609902D0/en
Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en
Priority claimed from GB0620337A external-priority patent/GB0620337D0/en
Priority claimed from GB0620815A external-priority patent/GB0620815D0/en
Priority claimed from GB0620816A external-priority patent/GB0620816D0/en
Priority claimed from PCT/GB2006/004634 external-priority patent/WO2007068907A2/fr
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA30066B1 publication Critical patent/MA30066B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des vaccins pneumococciques â base de conjugués de saccharides capsulaires. Plus particulièrement, elle concerne une composition immunogène pour nourrissons comprenant un vaccin à Streptococçus pneumoniae multivalent renfermant au moins 2 conjugués de saccharides capsulaires issus de sérotypes différents, la composition comprenant un conjugué saccharidique de sérotype 22F. Ce vaccin peut être utilisé dans des populations de nourrissons en vue de réduire l'incidence d'une maladie pneumococcique chez les personnes âgées, et notamment les exacerbations de la BPCO et/ou de la maladie pneumococcique invasive.
MA31050A 2005-12-22 2008-06-18 Vaccin MA30066B1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0526232A GB0526232D0 (en) 2005-12-22 2005-12-22 Vaccine
GB0607087A GB0607087D0 (en) 2006-04-07 2006-04-07 Vaccine
GBGB0607088.2A GB0607088D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
PCT/GB2006/004634 WO2007068907A2 (fr) 2005-12-13 2006-12-12 Nouvelle composition

Publications (1)

Publication Number Publication Date
MA30066B1 true MA30066B1 (fr) 2008-12-01

Family

ID=39133667

Family Applications (3)

Application Number Title Priority Date Filing Date
MA31049A MA30065B1 (fr) 2005-12-22 2008-06-18 Vaccin
MA31046A MA30062B1 (fr) 2005-12-22 2008-06-18 Vaccin
MA31050A MA30066B1 (fr) 2005-12-22 2008-06-18 Vaccin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA31049A MA30065B1 (fr) 2005-12-22 2008-06-18 Vaccin
MA31046A MA30062B1 (fr) 2005-12-22 2008-06-18 Vaccin

Country Status (36)

Country Link
US (10) US20090017072A1 (fr)
EP (10) EP2402025A3 (fr)
JP (7) JP5461838B2 (fr)
KR (5) KR101441368B1 (fr)
CN (6) CN101374548B (fr)
AR (3) AR058592A1 (fr)
AT (1) ATE520415T1 (fr)
AU (4) AU2006327036B2 (fr)
BR (3) BRPI0620460B8 (fr)
CA (5) CA2816182C (fr)
CL (1) CL2013002106A1 (fr)
CR (2) CR10119A (fr)
CY (5) CY1112677T1 (fr)
DK (5) DK1973564T3 (fr)
EA (3) EA014649B1 (fr)
ES (4) ES2630759T3 (fr)
HR (4) HRP20161682T1 (fr)
HU (3) HUE033081T2 (fr)
IL (5) IL191913A (fr)
JO (1) JO2813B1 (fr)
LT (3) LT3017827T (fr)
MA (3) MA30065B1 (fr)
MX (2) MX354843B (fr)
MY (4) MY147495A (fr)
NO (4) NO345368B1 (fr)
NZ (4) NZ569076A (fr)
PE (2) PE20071305A1 (fr)
PH (1) PH12014502544A1 (fr)
PL (5) PL1968631T3 (fr)
PT (5) PT1962899E (fr)
SG (1) SG168517A1 (fr)
SI (5) SI1973564T1 (fr)
TR (1) TR201900418T4 (fr)
TW (4) TWI487534B (fr)
UA (2) UA96583C2 (fr)
WO (3) WO2007071710A2 (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1449293B (zh) * 2000-06-29 2012-08-22 史密丝克莱恩比彻姆生物有限公司 多价疫苗组合物
CA2428103C (fr) 2000-11-07 2015-06-09 Immunovaccine Technologies Inc. Vaccins a reponse immunitaire accrue et leurs procedes de preparation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
BRPI0612655B1 (pt) * 2005-06-27 2021-06-15 Pfizer Ireland Pharmaceuticals Composição imunogênica
KR101441368B1 (ko) 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
EP2081953A2 (fr) * 2006-08-17 2009-07-29 The UAB Research Foundation Polypeptides immunogeniques de pcpa e leur utilisations
EP2155244B1 (fr) * 2007-04-23 2017-03-22 Serum Institute of India Private Limited Polysaccharides antigéniques et procédé pour leur préparation
JP2010525035A (ja) * 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
DK2167121T3 (en) * 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009039628A1 (fr) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Utilisation de liposomes dans un véhicule composant une phase hydrophobe continue pour la délivrance de polynucléotides in vivo
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
WO2009094730A1 (fr) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Compositions de vaccin
HUE026586T2 (hu) * 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vakcina
CN102065889A (zh) * 2008-04-16 2011-05-18 葛兰素史密丝克莱恩生物有限公司 疫苗
EP2293815A4 (fr) * 2008-05-22 2013-04-03 Childrens Medical Center Conjugué immunogène synergique protéine de fusion-polysaccharide
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (fr) 2008-12-17 2010-06-24 Novartis Ag Vaccins méningococciques comprenant un récepteur de l'hémoglobine
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756398A1 (fr) * 2009-03-24 2010-09-30 Novartis Ag Combinaisons comprenant un saccharide de pneumocoque serotype 14
CN102438649A (zh) * 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
ES2552153T3 (es) * 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Vacuna neumocócica y usos de la misma
WO2010141312A2 (fr) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Protéines de fusion flagelline et conjugués comprenant des antigènes pneumocoques et leurs procédés d'utilisation
EP2475385A1 (fr) 2009-09-10 2012-07-18 Novartis AG Vaccins combinés contre les maladies des voies respiratoires
KR20110068831A (ko) * 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CA2803239A1 (fr) 2010-06-25 2011-12-29 Novartis Ag Associations de proteines de liaison du facteur h meningococcique
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
CA2828844C (fr) * 2011-03-02 2020-07-14 Novartis Ag Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US20140072622A1 (en) * 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2850857C (fr) 2011-10-06 2022-07-26 Immunovaccine Technologies Inc. Compositions liposomales comprenant un adjuvant qui active ou accroit l'activite de tlr2 et utilisations associees
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
DK2809349T3 (da) * 2012-01-30 2019-02-18 Serum Institute Of India Pvt Ltd Immunogen sammensætning
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
EP2811981B1 (fr) * 2012-02-07 2019-05-08 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
CN104519910B (zh) * 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
EP2822584A1 (fr) 2012-03-08 2015-01-14 Novartis AG Vaccins combinés comprenant des agonistes du tlr4
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2510281C2 (ru) * 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
SG11201500566XA (en) 2012-08-16 2015-04-29 Pfizer Glycoconjugation processes and compositions
CA2882619A1 (fr) 2012-09-06 2014-03-13 Novartis Ag Vaccins combinatoires avec meningococcus de serogroupe b et d/t/p
CN109289045A (zh) * 2012-09-19 2019-02-01 国立大学法人大阪大学 含有肺炎球菌表面蛋白a的肺炎球菌疫苗
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
BR112015014250A2 (pt) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa método para imunizar um bebê, vacina de combinação e, kit
PL2935299T3 (pl) * 2012-12-20 2020-05-18 Pfizer Inc. Sposób glikokoniugacji
RU2544168C1 (ru) * 2014-01-17 2015-03-10 Андрей Дмитриевич Протасов Способ формирования иммунологической памяти к антигенам streptococcus pneumoniae у пациентов с хронической обструктивной болезнью легких
CN110859957B (zh) * 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CN112336854B (zh) * 2014-01-21 2024-11-26 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3443983B1 (fr) * 2014-02-14 2022-07-20 Pfizer Inc. Conjugués immunogènes de glycoprotéine
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
CN103936842B (zh) * 2014-04-30 2016-03-23 重庆医科大学 肺炎链球菌溶血素突变体及其作为粘膜免疫佐剂的应用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
AU2015348922B2 (en) * 2014-11-20 2020-01-23 Biological E Limited Codon optimized polynucleotide for high level expression of CRM197
KR102710711B1 (ko) * 2015-03-26 2024-09-25 지피앤 백신즈 피티와이 엘티디 연쇄상구균 백신
NZ736238A (en) 2015-05-04 2022-07-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
RU2600838C1 (ru) * 2015-06-08 2016-10-27 Андрей Дмитриевич Протасов Способ усиления активности факторов неспецифической защиты у пациентов с хронической обструктивной болезнью легких
AU2016276269B2 (en) * 2015-06-08 2021-01-28 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
KR20160146240A (ko) 2015-06-12 2016-12-21 전관구 염기성 계면활성제를 이용한 산화은나노 및 은나노 제조 방법
HUE053272T2 (hu) 2015-06-23 2021-06-28 Biological E Ltd Multivalens konjugált pneumococcus vakcina
KR20210027523A (ko) * 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
MY199342A (en) * 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP4309670A3 (fr) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Vaccin contre neisseria meningitidis
CN109982715A (zh) * 2016-09-27 2019-07-05 免疫疫苗技术有限公司 利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法
NZ792866A (en) 2016-09-30 2025-10-31 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
US11027005B2 (en) 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
WO2018080213A1 (fr) * 2016-10-28 2018-05-03 주식회사 엘지화학 Composition immunogène multivalente ayant un titre d'igg augmenté, et son utilisation
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
EP3562838A2 (fr) 2016-12-28 2019-11-06 Henriques Normark, Birgitta Microparticules destreptococcus pneumoniae
CN110366428B (zh) * 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018208844B2 (en) * 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
DK3585803T3 (da) 2017-02-24 2025-12-15 Merck Sharp & Dohme Llc Formuleringer af pneumokokkal konjugatvaccine
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107929728A (zh) * 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 一种肺炎球菌蛋白疫苗及其制备方法
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 创赏公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
WO2019043245A1 (fr) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine Cellules microbiennes exprimant des sérotypes streptococciques
HRP20241185T1 (hr) 2017-09-07 2024-11-22 Merck Sharp & Dohme Llc Pneumokokni polisaharidi i njihova primjena u imunogenim konjugatima polisaharid-proteinski nosač
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074711A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugues immunogenes polysaccharide-proteine porteuse
JP2020533299A (ja) 2017-09-07 2020-11-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． キャリアタンパク質へのコンジュゲーションのための肺炎球菌多糖の製剤方法
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN111757754B (zh) 2018-02-05 2024-07-05 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
MY205174A (en) 2018-02-05 2024-10-04 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20190121713A (ko) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
CN112543649A (zh) * 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
CN112969474A (zh) * 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
JP7558944B2 (ja) * 2018-10-12 2024-10-01 バイオロジカル イー リミテッド 多価肺炎球菌多糖類－タンパク質コンジュゲートワクチン
WO2020121159A1 (fr) * 2018-12-12 2020-06-18 Pfizer Inc. Conjugués polysaccharide-protéine immunogènes à hétéroantigènes multiples et leurs utilisations
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
KR20210010412A (ko) * 2019-07-18 2021-01-27 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
US12377118B2 (en) * 2019-08-09 2025-08-05 Case Western Reserve University Nanoparticle constructs for systemic co-delivery of anti-tumor agents
US12473379B2 (en) 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
EP4017478A1 (fr) 2019-09-18 2022-06-29 Alcon Inc. Inserts oculaires d'hydrogel mou conditionnés par voie humide
WO2021056098A1 (fr) * 2019-09-23 2021-04-01 Koranex Capital Néoglycoconjugués utilisés en tant que vaccins et outils thérapeutiques
AU2021207701B2 (en) * 2020-01-17 2025-08-14 Bill & Melinda Gates Foundation Multivalent Streptococcus vaccines
KR20210117663A (ko) 2020-03-20 2021-09-29 주식회사 보고 수직형 침지식 dpf 세척장치
CA3191005A1 (fr) 2020-08-10 2022-02-17 Inventprise, Inc. Vaccins glycoconjugues pneumococciques multivalents contenant un serotype 24f emergent
CN113293115B (zh) * 2021-07-08 2022-08-26 成都生物制品研究所有限责任公司 肺炎链球菌无动物源冻干保护剂
KR20240055283A (ko) 2022-10-20 2024-04-29 우남철 Ｄｐｆ용 순환펌프 연결구
WO2024180472A1 (fr) 2023-02-28 2024-09-06 Alcon Inc. Dispositifs oculaires

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (fr) 1979-09-21 1986-04-16 Hitachi, Ltd. Interrupteur à semiconducteur
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
EP0362278A4 (fr) 1987-06-05 1990-05-14 Us Health Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer.
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2160570T3 (es) 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
CA2006700A1 (fr) 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (fr) 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
ES2118812T3 (es) 1991-02-15 1998-10-01 Uab Research Foundation Gen estructural de proteina pneumococica.
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
DE69324487T2 (de) 1992-05-06 1999-08-12 The President and Fellows of Harvard College, Cambridge, Mass. Rezeptorbindende region des diphtherietoxius
AU671649B2 (en) 1992-06-18 1996-09-05 President And Fellows Of Harvard College Diphtheria toxin vaccines
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
RU2154068C2 (ru) 1993-11-17 2000-08-10 Лаборатуар Ом С.А. Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (fr) 1994-03-07 1995-09-14 Bioject, Inc. Dispositif de remplissage d'ampoule
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
DE69628418T2 (de) * 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US7184826B2 (en) 1996-06-18 2007-02-27 Alza Corporation Device and method for enhancing transdermal flux of agents being delivered or sampled
WO1998006734A1 (fr) 1996-08-16 1998-02-19 Smithkline Beecham Corporation Nouveaux polynucleotides et polypeptides procaryotes et leurs utilisations
CA2269663A1 (fr) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Antigenes et vaccins actifs contre streptococcus pneumoniae
JP2002503087A (ja) 1996-11-12 2002-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニアのｃ３結合タンパク質
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2195190T3 (es) 1996-12-20 2003-12-01 Alza Corp Dispositivo y metodo para mejorar el flujo de agente transdermico.
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP1000144B1 (fr) 1997-06-03 2007-12-12 Sanofi Pasteur Limited Gene du recepteur de la lactoferrine de moraxella
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6764686B2 (en) 1997-07-21 2004-07-20 Baxter International Inc. Modified immunogenic pneumolysin compositions as vaccines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (fr) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
KR20010024299A (ko) 1997-09-24 2001-03-26 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 사람 보체 ｃ3 분해단백질분해효소
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
HUP0101139A3 (en) 1997-12-02 2003-11-28 Powderject Vaccines Inc Madiso Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
NZ507983A (en) 1998-04-07 2004-03-26 St A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
KR100794394B1 (ko) 1998-04-07 2008-01-15 메디뮨 인코포레이티드 백신용 폐렴 구균의 콜린 결합성 단백질의 유도체
JP2002516251A (ja) 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
CN1352691A (zh) 1998-09-24 2002-06-05 美国明尼苏达州大学 来自肺炎链球菌的人补体c3降解性多肽
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
WO2000030299A1 (fr) 1998-11-17 2000-05-25 Schlumberger Technology Corporation Transmission de donnees dans une liaison de communications
AU2027400A (en) 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
EP2261358B1 (fr) 1998-12-23 2014-05-14 ID Biomedical Corporation of Quebec Antigènes de Streptococcus
EP1034792A1 (fr) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus
DE122009000054I1 (de) * 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
WO2000061761A2 (fr) 1999-04-09 2000-10-19 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
HK1044484B (en) 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
ATE500843T1 (de) 1999-06-10 2011-03-15 Medimmune Llc Streptococcus pneumoniae proteine und impfstoffe
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
KR100927767B1 (ko) 2000-06-20 2009-11-20 아이디 바이오메디칼 코포레이션 스트렙토코커스 항원
CN1449293B (zh) * 2000-06-29 2012-08-22 史密丝克莱恩比彻姆生物有限公司 多价疫苗组合物
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2001281001B2 (en) 2000-08-04 2005-11-03 Corixa Corporation New immunoeffector compounds
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2292632A3 (fr) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation de l'activité immunostimulatrice d'analogues oligonucléotidiques immunostimulateurs par des modifications chimiques de position
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
FR2827199B1 (fr) 2001-07-10 2004-07-09 Centre Nat Rech Scient Procede et machine de fabrication ex situ de reseaux de biopuces basse et moyennes integration
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (fr) 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
WO2003054007A2 (fr) 2001-12-20 2003-07-03 Shire Biochem Inc. Antigenes de streptococcus
CN1301134C (zh) 2002-02-04 2007-02-21 科里克萨有限公司 新的免疫效应化合物
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
EP1524992B1 (fr) 2002-08-02 2015-03-04 GlaxoSmithKline Biologicals s.a. Vaccins comprenants de lipooligosaccharides de immunotype l2 et/ou l3 de lgtb- neisseria meningitide
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
JP3754420B2 (ja) 2003-02-04 2006-03-15 三洋電機株式会社 二次電池用電極板及びその製造方法並びにこの電極板を用いた二次電池
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
WO2004083251A2 (fr) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
CA2530364C (fr) 2003-06-23 2014-03-18 Baxter International Inc. Vaccins contre neisseria meningitidis du groupe y et combinaisons meningococciques desdits vaccins
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2005105140A2 (fr) 2004-04-30 2005-11-10 Chiron Srl Integration d'une vaccination conjuguee antimeningococcique
SI1748791T1 (sl) 2004-05-11 2010-07-30 Staat Der Nederlanden - Minister Van Vws Neisseria meningitidis IgtB LOS kot adjuvans
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
BRPI0612655B1 (pt) 2005-06-27 2021-06-15 Pfizer Ireland Pharmaceuticals Composição imunogênica
AU2006286228A1 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
EP1945249A2 (fr) 2005-11-01 2008-07-23 Novartis AG Compositions comprenant des antigenes adsorbes par du phosphate de calcium
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101441368B1 (ko) 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
WO2007127363A2 (fr) 2006-04-26 2007-11-08 Micell Technologies, Inc. Revêtements contenant plusieurs médicaments
DK2167121T3 (en) 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
ES2749952T3 (es) 2008-12-18 2020-03-24 Wyeth Llc Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono

Also Published As

Publication number Publication date
CA2816182A1 (fr) 2007-06-28
SI1968631T1 (sl) 2015-07-31
CA2634885A1 (fr) 2007-06-28
SG168517A1 (en) 2011-02-28
TWI487534B (zh) 2015-06-11
CY1116407T1 (el) 2017-02-08
MY160199A (en) 2017-02-28
KR20080081060A (ko) 2008-09-05
WO2007071711A3 (fr) 2007-11-08
NZ569076A (en) 2011-08-26
US20190262447A1 (en) 2019-08-29
EP2384765A3 (fr) 2012-06-20
US20090017059A1 (en) 2009-01-15
US20090010959A1 (en) 2009-01-08
CA2634887C (fr) 2016-01-19
HK1120230A1 (en) 2009-03-27
TW200738257A (en) 2007-10-16
EP2382986A3 (fr) 2012-08-22
TW200738258A (en) 2007-10-16
IL192084A (en) 2013-11-28
JP2009520761A (ja) 2009-05-28
PH12014502544A1 (en) 2015-12-14
JP5615323B2 (ja) 2014-10-29
IL192084A0 (en) 2008-12-29
BRPI0620163B8 (pt) 2021-05-25
MY147495A (en) 2012-12-14
PT1968631E (pt) 2015-07-20
AR058706A1 (es) 2008-02-20
JP2009520759A (ja) 2009-05-28
JP5749689B2 (ja) 2015-07-15
HRP20161682T1 (hr) 2017-01-27
DK1968631T3 (da) 2015-06-15
EP2402025A3 (fr) 2012-03-07
CN103585623B (zh) 2016-09-28
EA014165B1 (ru) 2010-10-29
CA2808919C (fr) 2016-04-19
JP2014205673A (ja) 2014-10-30
HUE041979T2 (hu) 2019-06-28
UA96583C2 (uk) 2011-11-25
US20180250389A9 (en) 2018-09-06
AU2006327041B2 (en) 2010-08-26
BRPI0620163B1 (pt) 2019-08-13
CA2633772C (fr) 2015-09-15
KR20080081063A (ko) 2008-09-05
US20220354941A1 (en) 2022-11-10
EP1962899A2 (fr) 2008-09-03
WO2007071707A3 (fr) 2007-09-13
KR101365001B1 (ko) 2014-02-21
AR058592A1 (es) 2008-02-13
NZ569077A (en) 2011-08-26
US10279033B2 (en) 2019-05-07
BRPI0620163A2 (pt) 2011-11-01
CN101378778B (zh) 2013-02-06
PT2384765T (pt) 2017-02-06
LT1973564T (lt) 2016-12-27
US9884113B2 (en) 2018-02-06
AU2006327040A1 (en) 2007-06-28
PL3017827T3 (pl) 2019-04-30
JP2012232985A (ja) 2012-11-29
AU2010241281A1 (en) 2010-11-25
CA2816182C (fr) 2018-02-20
NO345368B1 (no) 2021-01-04
SI2384765T1 (sl) 2017-03-31
JP2012211165A (ja) 2012-11-01
CN103585623A (zh) 2014-02-19
CN110179974A (zh) 2019-08-30
CN101374548B (zh) 2013-05-01
SI1973564T1 (sl) 2017-02-28
PL2384765T3 (pl) 2017-05-31
WO2007071710A2 (fr) 2007-06-28
BRPI0620460B1 (pt) 2019-08-13
BRPI0620460B8 (pt) 2021-05-25
KR101418240B1 (ko) 2014-07-16
MY148141A (en) 2013-03-15
NO20082646L (no) 2008-09-16
US11400147B2 (en) 2022-08-02
IL191913A0 (en) 2009-02-11
IL211664A0 (en) 2011-05-31
NO20082718L (no) 2008-09-16
US20100074922A1 (en) 2010-03-25
HUE032903T2 (hu) 2017-11-28
KR101367237B1 (ko) 2014-03-14
EP2384765A2 (fr) 2011-11-09
TWI465248B (zh) 2014-12-21
NO346529B1 (no) 2022-09-26
US20150265702A1 (en) 2015-09-24
MX2008008140A (es) 2008-09-24
BRPI0620460A2 (pt) 2011-11-16
CN110179974B (zh) 2024-01-09
TR201900418T4 (tr) 2019-02-21
AU2006327036A1 (en) 2007-06-28
JP5600337B2 (ja) 2014-10-01
HRP20110685T1 (hr) 2011-10-31
LT3017827T (lt) 2019-01-10
DK2384765T3 (en) 2017-01-09
EP1973564A2 (fr) 2008-10-01
EP3130348A1 (fr) 2017-02-15
MY150719A (en) 2014-02-28
ATE520415T1 (de) 2011-09-15
KR20130103831A (ko) 2013-09-24
PT1973564T (pt) 2017-01-24
PT1962899E (pt) 2011-10-19
KR101515078B1 (ko) 2015-04-24
NZ569168A (en) 2012-02-24
IL191911A (en) 2015-09-24
DK1973564T3 (da) 2017-01-16
DK3017827T3 (en) 2019-02-18
CN103251940A (zh) 2013-08-21
KR20140036327A (ko) 2014-03-25
PE20071058A1 (es) 2007-11-27
CA2634887A1 (fr) 2007-06-28
ES2707499T3 (es) 2019-04-03
EP3017827B1 (fr) 2018-11-07
US20090017072A1 (en) 2009-01-15
AU2006327040B2 (en) 2010-08-19
AR058707A1 (es) 2008-02-20
HRP20190037T1 (hr) 2019-02-22
US20160243219A1 (en) 2016-08-25
SI3017827T1 (sl) 2019-01-31
CN101378779B (zh) 2015-09-02
MX354843B (es) 2018-03-22
EP1968631B1 (fr) 2015-04-08
ES2539795T3 (es) 2015-07-06
EA014649B1 (ru) 2010-12-30
CY1112677T1 (el) 2016-02-10
CY1118345T1 (el) 2017-06-28
NO20190104A1 (no) 2008-09-18
CN101374548A (zh) 2009-02-25
CN101378778A (zh) 2009-03-04
DK1962899T3 (da) 2011-10-31
US20150190521A1 (en) 2015-07-09
JP5792920B2 (ja) 2015-10-14
BRPI0620193B8 (pt) 2021-05-25
EA200801367A1 (ru) 2008-12-30
EP3017827A1 (fr) 2016-05-11
NO343981B1 (no) 2019-08-05
ES2614938T3 (es) 2017-06-02
MA30065B1 (fr) 2008-12-01
IL191913A (en) 2012-07-31
KR101441368B1 (ko) 2014-09-24
PT3017827T (pt) 2019-01-28
CN101378779A (zh) 2009-03-04
NO20082647L (no) 2008-09-18
SI1962899T1 (sl) 2011-11-30
EP3470080A1 (fr) 2019-04-17
JP5849125B2 (ja) 2016-01-27
EA200801374A1 (ru) 2008-12-30
PL1973564T3 (pl) 2017-04-28
EP2382986A2 (fr) 2011-11-02
JP5579387B2 (ja) 2014-08-27
PL1962899T3 (pl) 2011-12-30
LT2384765T (lt) 2017-01-10
NZ596500A (en) 2013-05-31
WO2007071707A2 (fr) 2007-06-28
EA200801344A1 (ru) 2008-12-30
EP2402025A2 (fr) 2012-01-04
UA96934C2 (uk) 2011-12-26
IL191911A0 (en) 2008-12-29
NO344187B1 (no) 2019-09-30
CL2013002106A1 (es) 2014-03-07
CA2633772A1 (fr) 2007-06-28
IL219641A0 (en) 2012-06-28
TW201350129A (zh) 2013-12-16
CY1121376T1 (el) 2020-05-29
JP2012229228A (ja) 2012-11-22
HUE033081T2 (hu) 2017-11-28
EP1968631A2 (fr) 2008-09-17
TWI415622B (zh) 2013-11-21
CR10122A (fr) 2008-08-21
EP1973564B1 (fr) 2016-11-09
KR20080081061A (ko) 2008-09-05
EP3020411A1 (fr) 2016-05-18
EP2384765B1 (fr) 2016-11-23
CA2808919A1 (fr) 2007-06-28
PE20071305A1 (es) 2007-12-14
CR10119A (fr) 2008-07-29
EA014107B1 (ru) 2010-10-29
JO2813B1 (en) 2014-09-15
BRPI0620193B1 (pt) 2019-12-31
EP1962899B1 (fr) 2011-08-17
IL219641A (en) 2017-10-31
US10646564B2 (en) 2020-05-12
HRP20161681T1 (hr) 2017-01-13
MA30062B1 (fr) 2008-12-01
BRPI0620193A2 (pt) 2011-11-01
WO2007071711A2 (fr) 2007-06-28
WO2007071710A8 (fr) 2008-09-04
WO2007071710A3 (fr) 2007-11-29
JP5461838B2 (ja) 2014-04-02
CA2634885C (fr) 2016-04-19
ES2630759T3 (es) 2017-08-23
US9107872B2 (en) 2015-08-18
PL1968631T3 (pl) 2015-08-31
AU2006327041A1 (en) 2007-06-28
AU2010241281B2 (en) 2012-12-06
JP2009520760A (ja) 2009-05-28
CY1118535T1 (el) 2017-07-12
AU2006327036B2 (en) 2012-11-15
US20180207262A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MA30066B1 (fr) Vaccin
WO2009000825A3 (fr) Vaccin
CY1114041T1 (el) Ενεσιμα εμβολια εναντι πολλαπλων οροομαδων μηνιγγιτιδοκοκκου
WO2007116028A3 (fr) Vaccin
AR053354A1 (es) Composicion de conjugado polisacarido neumococcico multivalente -proteina
WO2008079732A3 (fr) Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
BR0009166A (pt) Vacina
RU2004136299A (ru) Мукозальные вакцины с хитозановым адъювантом и/или антигенами менингококков
DK1835939T3 (da) Meningokokkonjugatvaccination
BRPI0510315A (pt) integração de vacinação com conjugado meningocócico
TH95746B (th) วัคซีนมัลติวาเลนท์ Streptococcus pneumoniae คอนจูเกตที่ประกอบรวมด้วยซีโรไทพ์ 22F แซคคาไรด์ คอนจูเกต
TH95745A (th) วัคซีน Streptococcus pneumoniae แคปซูลาร์พอลิแซคคาไรด์
AR112332A2 (es) Composición inmunogénica de streptococcus pneumoniae, kit, procedimiento
TH95745B (th) วัคซีน Streptococcus pneumoniae แคปซูลาร์ พอลิแซคคาไรด์